KRYS earnings: next report 2026-08-03, real EPS beat/miss history, analyst consensus Buy, P/E 43.46. Updated 2026-07-23.
Krystal Biotech (KRYS) Research Hub
Krystal Biotech (KRYS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 347 USD (-0.31%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 43.46, market cap 9.99B. This hub links to the full technical, earnings and options research available for KRYS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 347 USD (-0.31%) |
| 52-week range | 313.76 USD – 382.54 USD |
| Trend regime | Range |
| 14-day RSI | 61.9 (Bullish) |
| Trailing P/E | 43.46 |
| Market cap | 9.99B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-03 |
Available research for KRYS
Covered Call on KRYS: how it works, illustrative setup around the real 347 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KRYS: how it works, illustrative setup around the real 347 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KRYS: how it works, illustrative setup around the real 347 USD price, max profit/loss, breakeven and when to use it. Educational.
KRYS technical analysis: range, last 347 USD, RSI 61.9, 52w range 313.76 USD–382.54 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is KRYS in?
Krystal Biotech (KRYS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is KRYS in an uptrend or downtrend?
As of 2026-09-11, KRYS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KRYS's trailing P/E ratio?
KRYS's trailing P/E is 43.46, with a market cap of 9.99B. See the earnings research page for full valuation detail.
When does KRYS next report earnings?
KRYS is next scheduled to report earnings on 2026-08-03, with a consensus EPS estimate of 1.7 USD.